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Surveillance of the severe acute respiratory illness (SARI) in Brazil 
aims to characterize the circulation of the Influenza A and B viruses in 
hospitalized cases and deaths, having been expanded in 2012 to include 
other respiratory viruses. COVID-19 was detected in Brazil for the time in 
the 9th epidemiological week of 2020, and the test for the SARS-CoV-2 virus 
was included in the surveillance protocol starting in the 12th epidemiological 
week. This study’s objective was to investigate the pattern of hospitalizations 
for SARI in Brazil since the entry of SARS-CoV-2, comparing the temporal 
and age profiles and laboratory results to the years 2010 through 2019. In 
2020, hospitalizations for SARI, compiled from the date of the first confirmed 
case of COVID-19 up to the 12th week, exceeded the numbers observed during 
the same period in each of the previous 10 years. The age bracket over 60 
years was the most heavily affected, at higher than historical levels. There 
was a considerable increase in negative laboratory tests, suggesting circulation 
of a different virus from those already present in the panel. We concluded 
that the increase in hospitalizations for SARI, the lack of specific information 
on the etiological agent, and the predominance of cases among the elderly 
during the same period in which there was an increase in the number of new 
cases of COVID-19 are all consistent with the hypothesis that severe cases 
of COVID-19 are already being detected by SARI surveillance, placing an 
overload on the health system. The inclusion of testing for SARS-CoV-2 in the 
SARI surveillance protocol and the test’s effective nationwide deployment are 
extremely important for monitoring the evolution of severe COVID-19 cases 
in Brazil.




Programa de Computação Científica, Fundação Oswaldo Cruz.
Av. Brasil 4365, Rio de Janeiro, RJ 21045-900, Brasil.
leonardo.bastos@fiocruz.br
1 Programa de Computação Científica, Fundação Oswaldo 
Cruz, Rio de Janeiro, Brasil.
2 Department of Infectious Diseases Epidemiology, London 
School of Hygiene and Tropical Medicine, London, U.K.
3 Instituto Federal de Educação, Ciência e Tecnologia do Rio de 
Janeiro, Rio de Janeiro, Brasil.
4 Escola de Matemática Aplicada, Fundação Getúlio Vargas, Rio 
de Janeiro, Brasil.
This article is published in Open Access under the Creative Commons 
Attribution license, which allows use, distribution, and reproduction in 
any medium, without restrictions, as long as the original work is correctly 
cited.
Bastos LS et al.2
Cad. Saúde Pública 2020; 36(4):e00070120
Introduction
In Brazil, reporting of hospitalized cases of severe acute respiratory illness (SARI) has been done in 
the Information System on Diseases of Notification (SINAN) since the Influenza A (H1N1) pandemic 
in 2009 1. Initially, the surveillance protocol for SARI focused on identifying the hospitalized cases 
and deaths related to the Influenza A and B viruses, and since 2012 it has also included respiratory 
syncytial virus (RSV), Adenovirus, and Parainfluenza 1, 2, and 3 1,2. With the arrival of COVID-19 
and the detection of community transmission in Brazil, the protocol has also included the test for 
SARS-CoV-2, starting in the 12th epidemiological week 3.
RT-PCR testing for SARS-CoV-2 in SARI surveillance has been introduced in Brazil in the midst 
of growing spread of this virus in the country and challenges for the pandemic’s containment and 
mitigation 3. In this context, the study aims to assess whether the entry of SARS-CoV-2 in Brazil 
altered the pattern of hospitalizations for SARI. In particular, the study compares the evolution in the 
number of confirmed cases of COVID-19 and SARI cases from the 9th to the 12th epidemiological 
weeks of 2020 and the hospitalization rates for SARI from 2010 to 2020, stratified by age bracket and 
the results of laboratory tests for the identification of respiratory viruses. The hypothesis is that the 





Due to the necessary readjustment of the country’s protocols and information system, new cases of 
COVID-19 were not available publicly in the system, but rather in epidemiological reports and bul-
letins produced by State Health Departments and the Brazilian Ministry of Health. In this context, 
the cases recorded from the 9th epidemiological week of 2020 (when the first case was confirmed) 
through the 12th week were collected by two independent data aggregators. The first aggregator was 
developed by Wesley Cota 5 and made available at the website https://labs.wesleycota.com/sarscov2/
br/ and will be referred to here as “COVID-19 (WC)”. The second was developed by Álvaro Justen 
et al. and made available at the website https://Brazil.io/dataset/covid19/boletim and will be called 
“COVID-19 (AJ et al.)”.
•	 SARI
The following are defined as SARI cases and are subject to compulsory notification, namely individu-
als with a combination of the following symptoms 6:
(i) High fever (> 37.8ºC) AND
(ii) Cough OR sore throat AND
(iii) Difficulty breathing OR dyspnea OR O2 saturation < 95% AND
(iv) Required hospitalization OR evolved to death having presented the symptoms above, regardless 
of hospitalization.
The numbers of new cases of hospitalization for SARI in Brazil by age bracket and year from 2010 
through 2020, from the 9th to the 12th epidemiological weeks of each year, as well as the results of 
laboratory tests performed in these patients, were extracted from SINAN and the Influenza Surveil-
lance System (SIVEP/Gripe), which replaced SINAN for notification of SARI beginning in 2019. 
The predicted count of SARI cases for the above-mentioned weeks was extracted from the Infogripe 
system (http://info.gripe.fiocruz.br), which uses a Bayesian statistical method to correct for report-
ing delay 7. This method is used in routine influenza surveillance, according to the contingency plan 
established by the Brazilian Ministry of Health 8. The Infogripe system is the result of a partnership 
between the Brazilian Ministry of Health, the Scientific Computing Program of the Oswaldo Cruz 
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Foundation (http://www.procc.fiocruz.br), and the School of Applied Mathematics of the Getulio 
Vargas Foundation (https://emap.fgv.br/).
The SARI data used here were inserted into the system up to March 21st, the last day of the 12th 
epidemiological week.
Analyses
We calculated the absolute numbers of new COVID-19 cases per epidemiological week for the year 
2020 and of hospitalizations due to SARI for the years 2010 through 2020, stratified by age brackets. 
To assess the effect of the entry of COVID-19 in Brazil on notifications of hospitalizations due to 
SARI, a descriptive analysis was performed in the R software, version 3.6.3 (http://www.r-project.org).
Results
COVID-19 was reported for the first time in Brazil in the 9th epidemiological week of 2020, totaling 
two cases. Figure 1 shows the evolution in the number of cases starting that week until the 12th epi-
demiological week. During that period there was an upward trend in the rate of COVID-19 notifica-
tions, surpassing 100 cases in the 11th epidemiological week and 1,000 cases in the 12th week. The 
hospitalization rate due to SARI also showed an upward trend during the same period, with the num-
ber of cases in the 11th epidemiological week (n = 1,365) having doubled that of the previous week 
(n = 691). For comparison, the historical median in non-epidemic years was 266 SARI hospitaliza-
tions in the 11th week and 299 in the 12th week. According to the estimate for SARI with correction 
for reporting delay, the real occurrence of hospitalizations for SARI in the 12th week is actually 59% 
higher than reported thus far. Using this correction, there was an observed increase in SARI, concur-
rently with the arrival of COVID-19 (Figure 1).
The years with the most hospitalizations for SARI were 2010, 2016, 2019, and 2020 (with n = 
1,826, n = 3,821, n = 3,305, and n = 4,056 hospitalizations, respectively). These values are higher than 
the mean value in the other years, considering the same time period (n = 951.3 hospitalizations/year). 
Figure 2 shows the hospitalizations for SARI from the 9th to 12th epidemiological weeks for the years 
2010 through 2020, stratified by age bracket. Age stratification shows that the 0 to 2-year age bracket 
had the highest proportion of hospitalizations every year except 2020, when the highest proportion 
was in individuals 60 years or older (26.7%).
Figure 3 shows the proportions of laboratory test results for the respiratory viruses in the panel, 
namely Influenza A and B, Parainfluenza types 1, 2, and 3, RSV, and Adenovirus among the hospital-
ized cases of SARI from the 9th to the 12th epidemiological weeks in the years 2010 through 2020. 
From 2010 e 2018, between 50% and 70% of the tests performed were negative for the tested viruses, 
while in 2019 and 2020, the proportions of negative tests increased to 72.1% and 94.5%, respectively. 
In the years with the most hospitalizations for SARI (2010, 2016, 2019, and 2020), Influenza A virus 
was detected in 12.5%, 34.5%, 4.9%, and 2.8% of the SARI cases, respectively. In 2019, RSV was detect-
ed in 23.3% of the cases, while Influenza B, the Parainfluenza viruses, and Adenovirus were detected 
at most in 3%, 2%, and 1% of the SARI cases, respectively, in the years analyzed.
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Figure 1
Absolute numbers of confirmed COVID-19 cases using two data aggregators (solid red and orange lines), hospitalizations for severe acute respiratory 
illness – SARI (solid black line), and hospitalizations for SARI with correction for reporting delay (dotted line) and 95% confidence intervals (95%CI) for 
Brazil in 2020, according to epidemiological week.
COVID-19 (AJ et al.): aggregator developed by Álvaro Justen et al. (https://Brazil.io/dataset/covid19/boletim); COVID-19 (WC): aggregator developed by 
Wesley Cota (https://labs.wesleycota.com/sarscov2/br/).
Figure 2
Absolute numbers of cases of hospitalizations for severe acute respiratory illness (SARI) in Brazil from the 9th to 12th epidemiological weeks in years 
2010 through 2020, stratified by age brackets.
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Figure 3
Proportions of laboratory test results for identification of Influenza A and B, Parainfluenza (types 1, 2, and 3), respiratory 
syncytial virus (RSV), and Adenovirus, among cases of hospitalization for severe acute respiratory illness (SARI) in Brazil 
from the 9th to 12th epidemiological weeks in the years 2010 through 2020.
Discussion
In 2020, hospitalizations for SARI since the detection of the first case of COVID-19 in Brazil exceeded 
those observed in the same period in each of the previous 10 years, even considering the known 
reporting delay. The increase in hospitalizations for SARI in 2020, the lack of specific information on 
the hospitalizations’ etiological agent, and the predominance of cases in the elderly during the same 
period in which there was an increase in new COVID-19 cases is consistent with the hypothesis that 
COVID-19 is being detected by the SARI surveillance system, although it is not possible to prove this 
due to the lack of specific testing. In this case, the hospitalization of severe cases of COVID-19 are 
already creating an overload on the health system.
The high rate of negative laboratory test results in SARI surveillance is noteworthy, both histori-
cally and specifically in 2020. It is possible that part of this difficulty in obtaining positive results is due 
to problems with the quality of the collected samples, inappropriate handling, or processing delay 2. 
However, one cannot rule out the possible circulation of other etiological agents, different from those 
previously tested. Over the years, the composition of the test panel has been modified to widen the 
scope of surveillance, although it has always prioritized Influenza virus 8. The proportion of negative 
test results reached 91% in 2020, an unprecedented level.
The risk factors for hospitalization due to COVID-19 are age greater than 60 years and presence 
of comorbidities such as hypertension, diabetes, heart disease, and respiratory disease 9. This was the 
age bracket with the most hospitalizations for SARI in 2020.
The year 2019 was also atypical in terms of hospitalization for SARI. More than half of the cases 
that year occurred in children under two years of age, and the most frequently detected virus was RSV 
(23.3%). RSV has shown similar seasonality to that of Influenza in Brazil and has been identified world-
wide as the most common cause of acute respiratory infections in children, although it also causes 
respiratory disease in other age groups, especially in the elderly and adults with comorbidities 10.
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COVID-19 arrived in Brazil during the season of the year in which respiratory virus activity is 
generally low. Only in 2010 and 2016, SARI seasonality occurred earlier (in the late summer and 
autumn) in most of Brazil’s states 11, with a predominance of Influenza A virus. The increase in hos-
pitalizations for SARI so early in 2020 calls our attention, since there is an upward tendency in SARI 
cases between the autumn and winter, especially in higher-latitude states 11. In this scenario, it is 
worrisome that the persistence of the COVID-19 pandemic, alongside peaks in Influenza infections, 
may further overload the health system in the coming months, which justifies having anticipated the 
Influenza vaccination campaign in the country in 2020.
The hypothesis that the increase in the number of COVID-19 cases in Brazil is already revealing 
its importance as a cause of SARI in 2020 is consistent with the change in the profile of hospitaliza-
tions. Proof of the hypothesis requires the inclusion of SARS-CoV-2 testing in the SARI surveillance 
protocol and its effective nationwide implementation.
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Resumo
A vigilância de síndrome respiratória aguda grave 
(SRAG) no Brasil visa a caracterizar a circulação 
dos vírus Influenza A e B em casos hospitalizados 
e óbitos, tendo sido ampliada em 2012 para in-
cluir outros vírus respiratórios. A COVID-19 foi 
detectada no Brasil pela primeira vez na 9a sema-
na epidemiológica de 2020 e o teste para o vírus 
SARS-CoV-2 foi incluído no protocolo de vigilân-
cia a partir da 12a semana epidemiológica. O ob-
jetivo deste estudo foi investigar o padrão de hos-
pitalizações por SRAG no país após a entrada do 
SARS-CoV-2, comparando o perfil temporal, 
etário e de resultados laboratoriais com os anos 
de 2010 a 2019. Em 2020, a hospitalização por 
SRAG, contabilizada desde a data do primeiro 
caso de COVID-19 confirmado até a 12a semana, 
superou o observado, no mesmo período, em cada 
um dos 10 anos anteriores. A faixa etária acima 
de 60 anos foi a mais acometida, em nível acima 
do histórico. Houve um aumento considerável de 
testes laboratoriais negativos, sugerindo a circula-
ção de um vírus diferente dos presentes no painel. 
Concluímos que o aumento das hospitalizações por 
SRAG, a falta de informação específica sobre o 
agente etiológico e a predominância de casos entre 
idosos, no mesmo período de tempo em que cresce 
o número de casos novos de COVID-19, é coerente 
com a hipótese de que os casos graves da doença já 
estejam sendo detectados pela vigilância de SRAG 
com sobrecarga para o sistema de saúde. A inclu-
são da testagem para SARS-CoV-2 no protocolo de 
vigilância de SRAG e sua efetiva implementação 
são de grande importância para acompanhar a 
evolução dos casos graves da doença no país.
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Resumen
La vigilancia del síndrome respiratorio agudo gra-
ve (SRAG) en Brasil tiene como objetivo caracteri-
zar la circulación de los virus de la Influenza A y 
B en casos y muertes hospitalizadas, y se expandió 
en 2012 para incluir otros virus respiratorios. La 
COVID-19 se detectó en Brasil por la primera vez 
en la 9a semana epidemiológica de 2020, y el exa-
men test para el virus SARS-CoV-2 se incluyó en 
el protocolo de vigilancia a partir de la 12a semana 
epidemiológica. El objetivo de este estudio fue in-
vestigar el patrón de hospitalizaciones por SRAG 
en Brasil desde la entrada de SARS-CoV-2, com-
parando el perfil temporal y de edad y los resulta-
dos de laboratorio entre los años 2010 a 2019. En 
2020, las hospitalizaciones por SRAG, compiladas 
a partir de la fecha del primer caso confirmado de 
COVID-19 hasta la 12a semana, excedió los nú-
meros observados durante el mismo período en ca-
da uno de los 10 años anteriores. El grupo de edad 
mayor de 60 años fue el más afectado, a niveles 
superiores a los históricos. Hubo un aumento con-
siderable en las pruebas de laboratorio negativas, 
lo que sugiere la circulación de un virus diferente 
de los que ya están presentes en el panel. Se con-
cluye que el aumento de las hospitalizaciones por 
SRAG, la falta de información específica sobre el 
agente etiológico y el predominio de casos entre los 
ancianos en el mismo período en que hubo un au-
mento de casos nuevos de COVID-19 se entiende 
que con esta hipótesis de que los casos graves de 
COVID-19 ya estén siendo monitorados por la vi-
gilancia de SRAG, lo que genera una sobrecarga 
en el sistema de salud. La inclusión de los exáme-
nes para SARS-CoV-2 en el protocolo de vigilan-
cia de SRAG y la eficacia de implementación son 
de grande importancia para monitorear la evolu-
ción de los casos graves de COVID-19 en Brasil.
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